Índice de Salud Prostática (phi)

Resumen

El antígeno específico de próstata (PSA, del inglés, Prostate Specific Antigen) es una glicoproteína producida por la próstata, y es el marcador tumoral de mayor uso. Sin embargo, su baja especificidad para diferenciar entre cáncer de próstata y otras alteraciones no malignas, como la hipertrofia benigna de la próstata (HBP) y la prostatitis aguda, limitan su utilidad diagnóstica.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Ana Isabel Toro-Montoya, Editora Médica Colombiana

Bacterióloga y Laboratorista Clínica. MSc en Virología. Directora Científica, Editora Médica Colombiana S.A. Medellín, Colombia. https://orcid.org/0000-0002-9866-7000.

Jennifer C. Vizcaíno-Carruyo, Editora Médica Colombiana

Médica, Especialista en Hematología. Asistente Científica, Editora Médica Colombiana S.A. Medellín, Colombia. https://orcid.org/0000-0002-4218-1239.

Natalia M. Guevara-Arismendy, Laboratorio Clínico Hematológico S.A.

Microbióloga y Bioanalista. MSc en Microbiología y Bioanálisis con énfasis en Hematología. Coordinadora de Control y Aseguramiento de la Calidad, Laboratorio Clínico Hematológico S.A. Medellín, Colombia.
https://orcid.org/0000-0002-1266-1776.

Germán Campuzano-Zuluaga, Laboratorio Clínico Hematológico S.A.

Médico, Especialista en Medicina de Laboratorio y Patología Anatómica, Subespecialista en Hematopatología. Fellow, College of American Pathologists (FCAP). Director, Laboratorio Clínico Hematológico S.A. Director, Editora Médica Colombiana S.A. Medellín, Colombia. https://orcid.org/0000-0002-4356-3490.

Referencias bibliográficas

World Health Organization (WHO). Incidence, mortality and prevalence by cancer site. The Global Cancer Observatory (GLOBOCAN); 2020. 1-2. Acceso 06 de abril de 2021. Disponible en https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf.

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, et al. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J Natl Compr Canc Netw 2016;14:509-519. https://doi.org/10.6004/jnccn.2016.0060.

Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70. https://doi.org/10.1001/jama.294.1.66.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate cancer early detection. Plymouth Meeting, USA: 2018. 1-52. Acceso 15 de octubre de 2019. Disponible en https://www2.tri-kobe.org/nccn/guideline/urological/english/prostate_detection.pdf.

Vukovic I, Djordjevic D, Bojanic N, Babic U, Soldatovic I. Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range. International Braz J Urol 2017;43:48-56. https://doi.org/10.1590/S1677-5538.IBJU.2016.0256.

White J, Shenoy BV, Tutrone RF, Karsh LI, Saltzstein DR, Harmon WJ, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer Prostatic Dis 2018;21:78-84. https://doi.org/10.1038/s41391-017-0008-7.

Boegemann M, Stephan C, Cammann H, Vincendeau S, Houlgatte A, Jung K, et al. The percentage of prostate-specific antigen (PSA) isoform [–2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years. BJU International 2016;117:72-79. https://doi.org/10.1111/bju.13139.

Jain S, Pincus MR, Bluth MH, McPherson RA, Bowne WB, Lee P. Diganosis and management of cancer using serologic and other body fluid markers. In: Pincus MR, Bluth MH, McPherson RA, Bowne WB, eds. Henry´s Clinical Diagnosis and Management by Laboratory Methods. 23rd ed. St. Louis: Elsevier; 2017. p. 1442-1444.

Algeciras-Schimnich A. Insights: The Prostate Health Index (phi) in prostate cancer risk assessment. Minnesota, USA: Mayo Clinic Laboratories; 2017. Department of Laboratory Medicine and Pathology. Acceso 15 de octubre de 2019. Disponible en https://news.mayocliniclabs.com/2017/08/14/prostate-health-index-phi-prostate-cancer-risk-assessment-hot-topic/.

Özen H, Sözen S. PSA Isoforms in Prostate Cancer Detection. Eur Urol Supp 2006;5:495-499. https://doi.org/10.1016/j.eursup.2006.02.017.

Filella X, Foj L, Alcover J, Augé JM, Escudero JM, Molina R. ProPSA, un nuevo biomarcador para la detección y el manejo del cáncer de próstata. Rev Laboratorio Clín 2013;6:75-81. https://doi.org/10.1016/j.labcli.2013.01.006.

Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61:6958-6963.

U.S. Food & Drug Administration. Quantitative test for determination of [-2]proPSA levels. Silver Spring: FDA Summary of Safety and Effectiveness Data; 2012. 1-32. Acceso 15 de mayo de 2021. Disponible en https://www.accessdata.fda.gov/cdrh_docs/pdf9/P090026b.pdf.

Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, et al. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. Prostate Cancer Prostatic Dis 2017;20:228-233. https://doi.org/10.1038/pcan.2016.72.

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, et al. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol 2015;67:619-626. https://doi.org/10.1016/j.eururo.2014.10.010.

de la Calle C, Patil D, Wei JT, Scherr DS, Sokoll L, Chan DW, et al. Multicenter evaluation of the Prostate Health Index to detect aggressive prostate cancer in biopsy naive men. J Urol 2015;194:65-72. https://doi.org/10.1016/j.juro.2015.01.091.

Osses DF, Remmers S, Schroder FH, van der Kwast T, Roobol MJ. Results of prostate cancer screening in a unique cohort at 19yr of follow-up. Eur Urol 2019;75:374-377. https://doi.org/10.1016/j.eururo.2018.10.053.

Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikeeva E, Fossati N, et al. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: A review of the literature. Korean J Urol 2014;55:436-445. https://doi.org/10.4111/kju.2014.55.7.436.

Heidegger I, Klocker H, Pichler R, Pircher A, Prokop W, Steiner E, et al. ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study. Prostate Cancer Prostatic Dis 2017;20:271-275. https://doi.org/10.1038/pcan.2017.3.

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011;185:1650-1655. https://doi.org/10.1016/j.juro.2010.12.032.

Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial. Urol Oncol 2020;38:683.e681-683.e610. https://doi.org/10.1016/j.urolonc.2020.03.011.

Boegemann M, Arsov C, Hadaschik B, Herkommer K, Imkamp F, Nofer JR, et al. Discordant prostate specific antigen test results despite WHO assay standardization. Int J Biol Markers 2018;33:275-282. https://doi.org/10.1177/1724600818754750.

Stephan C, Bangma C, Vignati G, Bartsch G, Lein M, Jung K, et al. 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers. Int J Biol Markers 2009;24:65-69.

Vignati G, Giovanelli L. Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA. Int J Biol Markers 2007;22:295-301.

Stephan C, Kopke T, Semjonow A, Lein M, Deger S, Schrader M, et al. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? Clin Chem Lab Med 2009;47:1325-1331. https://doi.org/10.1515/CCLM.2009.285.

Foj L, Filella X, Alcover J, Auge JM, Escudero JM, Molina R. Variability of assay methods for total and free PSA after WHO standardization. Tumour Biol 2014;35:1867-1873. https://doi.org/10.1007/s13277-013-1249-2.

Ferguson J, Atkinson E, Rigsby P, Burns C. WHO International Collaborative Study of the proposed 2nd WHO is for total PSA (PSA-ACT + free PSA). Geneva, Switzerland: World Health Organization (WHO). Expert committee on biological standardization.; 2018. Acceso 03 de noviembre de 2020. Disponible en https://www.who.int/biologicals/BS.2018.2340_PSA_Total.pdf.

Prostate Cancer UK. The test PSA. London, UK: Prostate Cancer UK; 2020. Acceso 15 de julio de 2020. Disponible en https://prostatecanceruk.org/prostate-information/prostate-tests/psa-test.

Pagana KD, Pagana TJ. Mosby’s Manual of Diagnostic and Laboratory Test. 4th ed. Misuri, USA: Mosby Elsevier; 2010. ISBN: 9780323446648.

Bossens MM, Van Straalen JP, De Reijke TM, Kurth KH, Sanders GT. Kinetics of prostate-specific antigen after manipulation of the prostate. Eur J Cancer 1995;31a:682-685. https://doi.org/10.1016/0959-8049(95)00016-c.

Cómo citar
1.
Toro-Montoya AI, Vizcaíno-Carruyo JC, Guevara-Arismendy NM, Campuzano-Zuluaga G. Índice de Salud Prostática (phi). Med. Lab. [Internet]. 11 de enero de 2022 [citado 4 de octubre de 2022];26(1):91-8. Disponible en: https://medicinaylaboratorio.com/index.php/myl/article/view/563
Publicado
2022-01-11
Sección
ABC del laboratorio
Crossref Cited-by logo